TY - JOUR T1 - Growth Differentiation Factor-15 as a candidate biomarker in gynecologic malignancies: A meta-analysis JF - medRxiv DO - 10.1101/2020.07.07.20148221 SP - 2020.07.07.20148221 AU - Dipayan Roy AU - Anupama Modi AU - Manoj Khokhar AU - Manu Goyal AU - Shailja Sharma AU - Purvi Purohit AU - Puneet Setia AU - Antonio Facciorusso AU - Praveen Sharma Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/25/2020.07.07.20148221.abstract N2 - Growth Differentiation Factor-15 (GDF-15), though emerged as a novel marker in gynecological cancers, is yet to be recognized in clinical diagnostics. Eligible studies were sorted from multiple online databases, namely PubMed, Cochrane, ClinicalTrials.gov, Google Scholar, Web of Science, Embase, Scopus, LILACS, OpenGrey. From six studies, histopathologically diagnosed cases without prior treatment, and with diagnostic accuracy data for GDF-15 in gynecological cancers, were included. Our meta-analysis shows that GDF-15 has pooled diagnostic odds ratio of 12.74 at 80.5% sensitivity and 74.1% specificity, and an AUC of 0.84. Hence, GDF-15 is a potential marker to differentiate gynecological malignancy from non-malignant tumors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee (IEC), All India Institute of Medical Sciences (AIIMS), JodhpurAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable. ER -